Back to All Stocks

Divi's Laboratories (DIVISLAB) Stock Forecast

AI-powered analysis with bull/bear cases, price targets, and news sentiment

Divi's Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and custom synthesis, supplying global pharma companies.

Sector: Pharmaceuticals · AI-assisted analysis, refreshed periodically. Not financial advice. See our disclaimer.

Divi's Laboratories at a glance

Divi's Laboratories trades under the ticker DIVISLAB on the NSE (National Stock Exchange of India) and is classified in the Pharmaceuticals sector. This page brings together a live AI forecast, a discounted-cash-flow (DCF) valuation, and the fundamentals investors most often look at before taking a position.

Because Divi's Laboratories sits in the Pharmaceuticals space, its results tend to move with the drivers specific to that sector. The valuation framework below reflects the growth, risk and discount-rate assumptions we apply to Pharmaceuticals companies rather than a one-size-fits-all model.

How we value a Pharmaceuticals stock like Divi's Laboratories

Our 3-stage DCF model projects earnings for Divi's Laboratories using sector-calibrated growth: roughly 12.0% EPS growth in the high-growth phase (years 1–5), fading to about 9.0% (years 6–10), and a long-run terminal growth of 6.5%.

Those cash flows are discounted at an estimated cost of equity of 13.4%, built from a 7.0% risk-free rate, a sector beta of 0.75, and an equity risk premium of 8.5% (CAPM). The output is an intrinsic value per share and a "margin of safety" versus the current ₹ market price — shown live in the Valuation tab.

A below-market beta suggests Divi's Laboratories has historically been less volatile than the broader index, which usually points to a more defensive, lower-discount-rate profile.

Key things to watch with Divi's Laboratories

Before relying on any single number, sanity-check the inputs: is the current P/E reasonable versus Divi's Laboratories's own history and its Pharmaceuticals peers? Are earnings growing on a durable basis, or boosted by one-offs? How sensitive is the intrinsic value if growth comes in a couple of points below the sector assumption?

The AI Forecast tab adds qualitative colour — bull and bear cases, catalysts and risks — while the Valuation tab keeps the maths transparent. Treat both as a research starting point, not a recommendation.

Frequently asked questions about DIVISLAB

What sector does Divi's Laboratories (DIVISLAB) belong to?

Divi's Laboratories is classified in the Pharmaceuticals sector, alongside peers such as Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla. Sector classification drives the growth and risk assumptions used in its DCF valuation.

How is Divi's Laboratories's intrinsic value calculated?

We run a 3-stage discounted-cash-flow model using Pharmaceuticals-calibrated EPS growth (high-growth ~12.0%, fade ~9.0%, terminal 6.5%) discounted at an estimated cost of equity of 13.4%. The result is compared against the live ₹ price to give a margin of safety.

Is Divi's Laboratories a good long-term investment?

That depends on your goals, risk tolerance and the price you pay. This page gives you the tools — intrinsic value, margin of safety, P/E context and an AI bull/bear view — to make that judgement, but it is educational analysis and not financial advice. Always do your own research or consult a licensed adviser.

How often is the Divi's Laboratories analysis updated?

The live price and fundamentals refresh on each visit where data is available, while the AI commentary is regenerated periodically. The valuation recomputes from the latest price, so the margin of safety always reflects current market conditions.